81 FR 31650 - Prospective Grant of Exclusive Patent License: Development and Commercialization of Adeno-Virus Based Cancer Immunotherapy
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 81, Issue 97 (May 19, 2016)
National Institutes of Health
Federal Register Volume 81, Issue 97 (May 19, 2016)
| Page Range | 31650-31651 | |
| FR Document | 2016-11770 |
[Federal Register Volume 81, Number 97 (Thursday, May 19, 2016)] [Notices] [Pages 31650-31651] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-11770] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive Patent License: Development and Commercialization of Adeno-Virus Based Cancer Immunotherapy AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following Patents and Patent Applications to Etubics Corporation (``Etubics'') located in San Francisco, California, USA. Intellectual Property United States Provisional Patent Application No. 60/904,236 filed February 28, 2007, titled ``Brachyury Polypeptides and Methods of Use'' [HHS Reference No. E-074-2007/0-US-01]; International Patent Application No. PCT/US2008/055185filed February 28, 2008 titled ``Brachyury Polypeptides and Methods of Use'' [HHS Reference No. E-074-2007/0-PCT-02]; National Stage Applications and issued patents, in the US, EP, CA, AU, JP, HK, and all continuations applications, divisional applications and foreign counterpart applications and patents claiming priority to the provisional application no. 60/904,236, United States Provisional Patent Application No. 61/701,525, filed September 14, 2014, titled ``Brachyury Protein, Non-Poxvirus Non-Yeast Vectors Encoding Brachyury Protein, And Their Use'' [HHS Reference No. E-055-2011/0-US-01]; International Patent Application No. PCT/US2013/0059737 filed September 13, 2012 titled ``Brachyury Protein, Non-Poxvirus Non-Yeast Vectors Encoding Brachyury Protein, and Their Use'' [HHS Reference No. E-055-2011/0-PCT-02]; National Stage Applications and issued patents, in the U.S., EP and all continuations applications, divisional applications and foreign counterpart applications and patents claiming priority to the provisional application no. 60/701,525. U.S. Provisional Application No. 62/200,438 filed August 3, 2015 titled ``Brachyury Deletion Mutants, Non-Yeast Vectors Encoding Brachyury Deletion Mutants, and Their Use'' [HHS Reference No. E-244- 2015/0-US-01] and continuation applications, divisional applications and foreign counterpart applications claiming priority to the U.S. provisional application no. 62/200,438. U.S. Patent Application No. 61/582,723 filed January 3, 2012 entitled ``Native and Agonist CTL Epitopes of The MUC-1 Tumor Antigen'' [HHS Reference No. E-001-2012/0-US-01] as well as all continuation and divisional applications and foreign issued patents and patent applications claiming priority to the U.S. provisional application no. 61/582,723. U.S. Patent Application No. 61/894,482 filed October 23, 2013 entitled ``Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1-Oncoprotein'' [HHS Reference No. E-520-2013/0-US-01] as well as all continuation and divisional applications and foreign issued patents and patent applications claiming priority to the US provisional application no. 61/894,482. U.S. Patent No. 6,756,038 issued June, 29 2004 as well as issued and pending foreign counterparts [HHS Ref. No. E-099-1996/0-US-07]; U.S. Patent No. 7,723,096 issued May 25, 2010 as well as continuation and divisional applications, and issued and pending foreign counterparts [HHS Ref. No. E-099-1996/0-US-08]; Europe Patent No. 1017810 (HHS Ref. No. E-099-1996/0-EP-05, and all European contracting states in which this patent is validated, including: German Patent No. 69824023.5 (HHS Ref. No. E-099-1996/0-DE- 09); France Patent No. 1017810 (HHS Ref. No. E-099-1996/0-FR-10); Great Britain Patent No. 1017810 (HHS Ref. No. E-099-1996/0-GB-11); Italy Patent No. 1017810 (HHS Ref. No. E-099-1996/0-IT-12); Spain Patent No. 2217585) (HHS Ref. No. E-099-1996/0-ES-13); [[Page 31651]] Switzerland Patent Application No. 98948429.0 (now Switzerland Patent No. 1017810) (HHS Ref. No. E-099-1996/0-CH-14); Belgium Patent Application No. 98948429.0 (now Belgium Patent No. 1017810) (HHS Ref. No. E-099-1996/0-BE-15); Ireland Patent Application No. 98948429.0 (now Ireland Patent No. 1017810) (HHS Ref. No. E-099-1996/0-IE-16); and all continuations and divisional applications claiming priority to any of the above; Europe Patent Application No. 04011673.3 (now EP Patent No. 1447414) (HHS Ref. No. E-099-1996/0-EP-17), and all European contracting states in which this patent is validated, including: Austria Patent Application No. 04011673.3 (now Austria Patent No. 1447414) (HHS Ref. No. E-099-1996/0-AT-28); Belgium Patent Application No. 04011673.3 (now Belgium Patent No. 1447414) (HHS Ref. No. E-099- 1996/0-BE-29); Cyprus Patent Application No. 04011673.3 (now Cyprus Patent No. 1447414) (HHS Ref. No. E-099-1996/0-CY-31); Denmark Patent Application No. 04011673.3 (now Denmark Patent No. 1447414) (HHS Ref. No. E-099-1996/0-DK-41); Finland Patent Application No. 04011673.3 (now Finland Patent No. 1447414) (HHS Ref. No. E-099-1996/0-FI-33); France Patent Application No. 04011673.3 (now France Patent No. 1447414) (HHS Ref. No. E-099-1996/0-FR-42); Germany Patent Application No. 04011673.3 (now Germany Patent No. 69837896) (HHS Ref. No. E-099-1996/0-DE-40); Great Britain Patent Application No. 04011673.3 (now Great Britain Patent No. 1447414) (HHS Ref. No. E-099-1996/0-GB-43); Greece Patent Application No. 04011673.3 (now Greece Patent No. 1447414) (HHS Ref. No. E-099-1996/0-GR-34); Ireland Patent Application No. 04011673.3 (now Ireland Patent No. 1447414) (HHS Ref. No. E-099-1996/0-IE-35); Italy Patent Application No. 04011673.3 (now Italy Patent No. 1447414) (HHS Ref. No. E-099-1996/0-IT-36); Luxembourg Patent Application No. 04011673.3 (now Luxembourg Patent No. 1447414) (HHS Ref. No. E-099- 1996/0-LU-44); Monaco Patent Application No. 04011673.3 (now Monaco Patent No. 1447414) (HHS Ref. No. E-099-1996/0-MC-45); Netherlands Patent Application No. 04011673.3 (now Netherlands Patent No. 1447414) (HHS Ref. No. E-099-1996/0-NL-46); Portugal Patent Application No. 04011673.3 (now Portugal Patent No. 1447414) (HHS Ref. No. E-099-1996/ 0-PT-37); Spain Patent Application No. 04011673.3 (now Spain Patent No. 2286530) (HHS Ref. No. E-099-1996/0-ES-32); Sweden Patent Application No. 04011673.3 (now Sweden Patent No. 1447414) (HHS Ref. No. E-099- 1996/0-SE-38); Switzerland Patent Application No. 04011673.3 (now Switzerland Patent No. 1447414) (HHS Ref. No. E-099-1996/0-CH-30); and all continuations and divisional applications claiming priority to any of the above; Japan Patent Application No. 2000-516030 (now JP Patent No. 4291508) (HHS Ref. No. E-099-1996/0-JP-06), and all continuations and divisional applications claiming priority to this application; Australia Patent No. 745863 (HHS Ref. No. E-099-1996/0-AU-03), and all continuations and divisional applications claiming priority to this application; Canada Patent No. 2308127 (HHS Ref. No. E-099-1996/0-CA- 04), and all continuations and divisional applications claiming priority to this application; U.S. Patent Application No. 10/579,025 filed May 11, 2006 as well as all continuation and divisional applications, and issued and pending foreign counterparts [HHS Ref. No. E-087-2005/0-US-03]; U.S. Patent Application No. 10/579,007 filed May 11, 2006 as well as all continuation and divisional applications, and issued and pending foreign counterparts [HHS Ref. No. E-088-2005/0-US-03]; U.S. Patent No. 7,118,738 issued October 10, 2006 as well as all continuations and divisional applications, and issued and pending foreign counterparts [HHS Ref. No. E-154-1998/0-US-07]; U.S. Patent Application Nos. 08/686,280 filed July 25, 1996 as well as all issued and pending foreign counterparts [HHS Ref. No. E-259- 1994/3-US-01]; U.S. Patent No. 7,410,644 issued August 12, 2008 as well as all continuation and divisional applications, and issued and pending foreign counterparts [HHS Ref. No. E-259-1994/3-US-08]; The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of Licensed Patent Rights for the following: ``The development and commercialization of a therapeutic cancer vaccine specifically using Adeno-viral vectors.'' For avoidance of doubt, the field of use specifically excludes other viral vectors including but not limited to pox virus vectors, yeast based vectors and other adjuvants and vectors that are not adeno-viral vectors. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 3, 2016 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated exclusive license should be directed to: Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702 Telephone: (240)-276-5530; Facsimile: (240)- 276-5504E-mail: [email protected]. SUPPLEMENTARY INFORMATION: This invention concerns Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to normal human tissues. Stimulation of T cells with the Brachyury peptide promoted a robust immune response and the targeted lysis of invasive tumor cells. Brachyury overexpression has been demonstrated in a range of human tumors (breast, lung, colon and prostate, among others) suggesting that an immunotherapeutic product derived from this technology would be broadly applicable for the treatment of cancer. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7. Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Exclusive Patent License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: May 13, 2016. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2016-11770 Filed 5-18-16; 8:45 am] BILLING CODE 4140-01-P
![31650 Federal Register / Vol. 81, No. 97 / Thursday, May 19, 2016 / Notices
356: Major Opportunities for Research in Contact Person: Sung Sug Yoon, Ph.D., And Their Use’’ [HHS Reference No. E–
Epidemiology of Alzheimer’s Disease and Scientific Review Officer, Center for 055–2011/0–US–01];
Cognitive Resilience (R01). Scientific Review, National Institutes of International Patent Application No.
Date: June 14, 2016. Health, 6701 Rockledge Drive, Room 3152, PCT/US2013/0059737 filed September
Time: 1:00 p.m. to 4:00 p.m. Bethesda, MD 20892, sungsug.yoon@nih.gov.
Agenda: To review and evaluate grant
13, 2012 titled ‘‘Brachyury Protein, Non-
(Catalogue of Federal Domestic Assistance Poxvirus Non-Yeast Vectors Encoding
applications. Program Nos. 93.306, Comparative Medicine;
Place: National Institutes of Health, Brachyury Protein, and Their Use’’
93.333, Clinical Research, 93.306, 93.333,
Rockledge II, 6701 Rockledge Drive, 93.337, 93.393–93.396, 93.837–93.844,
[HHS Reference No. E–055–2011/0–
Bethesda, MD 20892, (Virtual Meeting). 93.846–93.878, 93.892, 93.893, National PCT–02]; National Stage Applications
Contact Person: George Vogler, Ph.D., Institutes of Health, HHS) and issued patents, in the U.S., EP and
Scientific Review Officer, Center for all continuations applications,
Scientific Review, National Institutes of Dated: May 12, 2016.
divisional applications and foreign
Health, 6701 Rockledge Drive, Room 3140, Carolyn Baum,
MSC 7770, Bethesda, MD 20892, (301) 237–
counterpart applications and patents
Program Analyst, Office of Federal Advisory claiming priority to the provisional
2693, voglergp@csr.nih.gov. Committee Policy.
Name of Committee: Surgical Sciences, application no. 60/701,525.
Biomedical Imaging and Bioengineering
[FR Doc. 2016–11771 Filed 5–18–16; 8:45 am] U.S. Provisional Application No. 62/
Integrated Review Group; Surgery, BILLING CODE 4140–01–P 200,438 filed August 3, 2015 titled
Anesthesiology and Trauma Study Section. ‘‘Brachyury Deletion Mutants, Non-
Date: June 15–16, 2016. Yeast Vectors Encoding Brachyury
Time: 8:00 a.m. to 5:00 p.m. DEPARTMENT OF HEALTH AND Deletion Mutants, and Their Use’’ [HHS
Agenda: To review and evaluate grant HUMAN SERVICES Reference No. E–244–2015/0–US–01]
applications. and continuation applications,
Place: Hilton Austin, 500 E 4th St, Austin, National Institutes of Health divisional applications and foreign
TX.
Contact Person: Weihua Luo, MD, Ph.D., counterpart applications claiming
Prospective Grant of Exclusive Patent
Scientific Review Officer, Center for priority to the U.S. provisional
License: Development and
Scientific Review, National Institutes of application no. 62/200,438.
Commercialization of Adeno-Virus U.S. Patent Application No. 61/
Health, 6701 Rockledge Drive, Room 5114,
MSC 7854, Bethesda, MD 20892, (301) 435–
Based Cancer Immunotherapy 582,723 filed January 3, 2012 entitled
1170, luow@csr.nih.gov. ‘‘Native and Agonist CTL Epitopes of
AGENCY: National Institutes of Health,
Name of Committee: Oncology 2— HHS. The MUC–1 Tumor Antigen’’ [HHS
Translational Clinical Integrated Review Reference No. E–001–2012/0–US–01] as
Group; Drug Discovery and Molecular ACTION: Notice. well as all continuation and divisional
Pharmacology Study Section. applications and foreign issued patents
Date: June 16–17, 2016. SUMMARY: This notice, in accordance
and patent applications claiming
Time: 8:00 a.m. to 5:00 p.m. with 35 U.S.C. 209 and 37 CFR part 404,
Agenda: To review and evaluate grant priority to the U.S. provisional
that the National Institutes of Health,
applications. application no. 61/582,723.
Department of Health and Human U.S. Patent Application No. 61/
Place: The Dupont Hotel, 1500 New Services, is contemplating the grant of
Hampshire Avenue NW., Washington, DC 894,482 filed October 23, 2013 entitled
20036.
an exclusive patent license to practice ‘‘Identification and Characterization of
Contact Person: Jeffrey Smiley, Ph.D., the inventions embodied in the HLA–A24 Agonist Epitopes of MUC1-
Scientific Review Officer, Center for following Patents and Patent Oncoprotein’’ [HHS Reference No. E–
Scientific Review, National Institutes of Applications to Etubics Corporation 520–2013/0–US–01] as well as all
Health, 6701 Rockledge Drive, Room 6194, (‘‘Etubics’’) located in San Francisco, continuation and divisional
MSC 7804, Bethesda, MD 20892, 301–594– California, USA.
7945, smileyja@csr.nih.gov. applications and foreign issued patents
Name of Committee: Bioengineering Intellectual Property and patent applications claiming
Sciences & Technologies Integrated Review priority to the US provisional
United States Provisional Patent application no. 61/894,482.
Group; Biomaterials and Biointerfaces Study Application No. 60/904,236 filed
Section. U.S. Patent No. 6,756,038 issued June,
Date: June 16–17, 2016.
February 28, 2007, titled ‘‘Brachyury 29 2004 as well as issued and pending
Time: 8:00 a.m. to 5:00 p.m. Polypeptides and Methods of Use’’ foreign counterparts [HHS Ref. No. E–
Agenda: To review and evaluate grant [HHS Reference No. E–074–2007/0–US– 099–1996/0–US–07];
applications. 01]; U.S. Patent No. 7,723,096 issued May
Place: Admiral Fell Inn, 888 South International Patent Application No. 25, 2010 as well as continuation and
Broadway, Baltimore, MD 21231. PCT/US2008/055185filed February 28, divisional applications, and issued and
Contact Person: Joseph D Mosca, Ph.D., 2008 titled ‘‘Brachyury Polypeptides
Scientific Review Officer, Center for pending foreign counterparts [HHS Ref.
Scientific Review, National Institutes of
and Methods of Use’’ [HHS Reference No. E–099–1996/0–US–08];
Health, 6701 Rockledge Drive, Room 5158, No. E–074–2007/0–PCT–02]; National Europe Patent No. 1017810 (HHS Ref.
MSC 7808, Bethesda, MD 20892, (301) 408– Stage Applications and issued patents, No. E–099–1996/0–EP–05, and all
9465, moscajos@csr.nih.gov. in the US, EP, CA, AU, JP, HK, and all European contracting states in which
Name of Committee: Healthcare Delivery continuations applications, divisional this patent is validated, including:
and Methodologies Integrated Review Group; applications and foreign counterpart German Patent No. 69824023.5 (HHS
Nursing and Related Clinical Sciences Study applications and patents claiming Ref. No. E–099–1996/0–DE–09); France
mstockstill on DSK3G9T082PROD with NOTICES
Section. priority to the provisional application Patent No. 1017810 (HHS Ref. No. E–
Date: June 16–17, 2016. no. 60/904,236, 099–1996/0–FR–10); Great Britain
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
United States Provisional Patent Patent No. 1017810 (HHS Ref. No. E–
applications. Application No. 61/701,525, filed 099–1996/0–GB–11); Italy Patent No.
Place: Bethesda North Marriott Hotel & September 14, 2014, titled ‘‘Brachyury 1017810 (HHS Ref. No. E–099–1996/0–
Conference Center, 5701 Marinelli Road, Protein, Non-Poxvirus Non-Yeast IT–12); Spain Patent No. 2217585) (HHS
Bethesda, MD 20852. Vectors Encoding Brachyury Protein, Ref. No. E–099–1996/0–ES–13);
VerDate Sep<11>2014 18:47 May 18, 2016 Jkt 238001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\19MYN1.SGM 19MYN1](https://thefederalregister.org/doc/81_FR_31747/page/1.svg)
![Federal Register / Vol. 81, No. 97 / Thursday, May 19, 2016 / Notices 31651
Switzerland Patent Application No. Patent No. 2286530) (HHS Ref. No. E– adjuvants and vectors that are not
98948429.0 (now Switzerland Patent 099–1996/0–ES–32); Sweden Patent adeno-viral vectors.
No. 1017810) (HHS Ref. No. E–099– Application No. 04011673.3 (now DATES: Only written comments and/or
1996/0–CH–14); Belgium Patent Sweden Patent No. 1447414) (HHS Ref. applications for a license which are
Application No. 98948429.0 (now No. E–099–1996/0–SE–38); Switzerland received by the NIH Office of
Belgium Patent No. 1017810) (HHS Ref. Patent Application No. 04011673.3 Technology Transfer on or before June
No. E–099–1996/0–BE–15); Ireland (now Switzerland Patent No. 1447414) 3, 2016 will be considered.
Patent Application No. 98948429.0 (HHS Ref. No. E–099–1996/0–CH–30);
ADDRESSES: Requests for copies of the
(now Ireland Patent No. 1017810) (HHS and all continuations and divisional
patent application, inquiries, and
Ref. No. E–099–1996/0–IE–16); and all applications claiming priority to any of
comments relating to the contemplated
continuations and divisional the above;
Japan Patent Application No. 2000– exclusive license should be directed to:
applications claiming priority to any of Sabarni K. Chatterjee, Ph.D., M.B.A.
the above; 516030 (now JP Patent No. 4291508)
(HHS Ref. No. E–099–1996/0–JP–06), Senior Licensing and Patenting
Europe Patent Application No. Manager, NCI Technology Transfer
04011673.3 (now EP Patent No. and all continuations and divisional
applications claiming priority to this Center, 9609 Medical Center Drive, RM
1447414) (HHS Ref. No. E–099–1996/0– 1E530 MSC 9702, Bethesda, MD 20892–
EP–17), and all European contracting application;
Australia Patent No. 745863 (HHS 9702 (for business mail), Rockville, MD
states in which this patent is validated, 20850–9702 Telephone: (240)-276–5530;
Ref. No. E–099–1996/0–AU–03), and all
including: Austria Patent Application Facsimile: (240)-276–5504E-mail:
continuations and divisional
No. 04011673.3 (now Austria Patent No. chatterjeesa@mail.nih.gov.
applications claiming priority to this
1447414) (HHS Ref. No. E–099–1996/0– SUPPLEMENTARY INFORMATION: This
application; Canada Patent No. 2308127
AT–28); Belgium Patent Application No. invention concerns Brachyury, a master
(HHS Ref. No. E–099–1996/0–CA–04),
04011673.3 (now Belgium Patent No. transcription factor that governs the
and all continuations and divisional
1447414) (HHS Ref. No. E–099–1996/0– epithelial-mesenchymal transition, was
applications claiming priority to this
BE–29); Cyprus Patent Application No. shown to be significantly overexpressed
application;
04011673.3 (now Cyprus Patent No. U.S. Patent Application No. 10/ in primary and metastasizing tumors
1447414) (HHS Ref. No. E–099–1996/0– 579,025 filed May 11, 2006 as well as relative to normal human tissues.
CY–31); Denmark Patent Application all continuation and divisional Stimulation of T cells with the
No. 04011673.3 (now Denmark Patent applications, and issued and pending Brachyury peptide promoted a robust
No. 1447414) (HHS Ref. No. E–099– foreign counterparts [HHS Ref. No. E– immune response and the targeted lysis
1996/0–DK–41); Finland Patent 087–2005/0–US–03]; of invasive tumor cells. Brachyury
Application No. 04011673.3 (now U.S. Patent Application No. 10/ overexpression has been demonstrated
Finland Patent No. 1447414) (HHS Ref. 579,007 filed May 11, 2006 as well as in a range of human tumors (breast,
No. E–099–1996/0–FI–33); France all continuation and divisional lung, colon and prostate, among others)
Patent Application No. 04011673.3 applications, and issued and pending suggesting that an immunotherapeutic
(now France Patent No. 1447414) (HHS foreign counterparts [HHS Ref. No. E– product derived from this technology
Ref. No. E–099–1996/0–FR–42); 088–2005/0–US–03]; would be broadly applicable for the
Germany Patent Application No. U.S. Patent No. 7,118,738 issued treatment of cancer.
04011673.3 (now Germany Patent No. October 10, 2006 as well as all The prospective exclusive license will
69837896) (HHS Ref. No. E–099–1996/ continuations and divisional be royalty bearing and will comply with
0–DE–40); Great Britain Patent applications, and issued and pending the terms and conditions of 35 U.S.C.
Application No. 04011673.3 (now Great foreign counterparts [HHS Ref. No. E– 209 and 37 CFR part 404.7. The
Britain Patent No. 1447414) (HHS Ref. 154–1998/0–US–07]; prospective exclusive license may be
No. E–099–1996/0–GB–43); Greece U.S. Patent Application Nos. 08/ granted unless within fifteen (15) days
Patent Application No. 04011673.3 686,280 filed July 25, 1996 as well as all from the date of this published notice,
(now Greece Patent No. 1447414) (HHS issued and pending foreign counterparts the NIH receives written evidence and
Ref. No. E–099–1996/0–GR–34); Ireland [HHS Ref. No. E–259–1994/3–US–01]; argument that establishes that the grant
Patent Application No. 04011673.3 U.S. Patent No. 7,410,644 issued of the license would not be consistent
(now Ireland Patent No. 1447414) (HHS August 12, 2008 as well as all with the requirements of 35 U.S.C. 209
Ref. No. E–099–1996/0–IE–35); Italy continuation and divisional and 37 CFR part 404.7.
Patent Application No. 04011673.3 applications, and issued and pending Complete applications for a license in
(now Italy Patent No. 1447414) (HHS foreign counterparts [HHS Ref. No. E– the prospective field of use that are filed
Ref. No. E–099–1996/0–IT–36); 259–1994/3–US–08]; in response to this notice will be treated
Luxembourg Patent Application No. The patent rights in these inventions as objections to the grant of the
04011673.3 (now Luxembourg Patent have been assigned and/or exclusively contemplated Exclusive Patent License
No. 1447414) (HHS Ref. No. E–099– licensed to the government of the Agreement. Comments and objections
1996/0–LU–44); Monaco Patent United States of America. The submitted to this notice will not be
Application No. 04011673.3 (now prospective exclusive license territory made available for public inspection
Monaco Patent No. 1447414) (HHS Ref. may be worldwide and the field of use and, to the extent permitted by law, will
No. E–099–1996/0–MC–45); may be limited to the use of Licensed not be released under the Freedom of
Netherlands Patent Application No. Patent Rights for the following: ‘‘The
mstockstill on DSK3G9T082PROD with NOTICES
Information Act, 5 U.S.C. 552.
04011673.3 (now Netherlands Patent development and commercialization of
No. 1447414) (HHS Ref. No. E–099– a therapeutic cancer vaccine specifically Dated: May 13, 2016.
1996/0–NL–46); Portugal Patent using Adeno-viral vectors.’’ For Richard U. Rodriguez,
Application No. 04011673.3 (now avoidance of doubt, the field of use Associate Director, Technology Transfer
Portugal Patent No. 1447414) (HHS Ref. specifically excludes other viral vectors Center, National Cancer Institute.
No. E–099–1996/0–PT–37); Spain Patent including but not limited to pox virus [FR Doc. 2016–11770 Filed 5–18–16; 8:45 am]
Application No. 04011673.3 (now Spain vectors, yeast based vectors and other BILLING CODE 4140–01–P
VerDate Sep<11>2014 18:47 May 18, 2016 Jkt 238001 PO 00000 Frm 00066 Fmt 4703 Sfmt 9990 E:\FR\FM\19MYN1.SGM 19MYN1](https://thefederalregister.org/doc/81_FR_31747/page/2.svg)
Document Created: 2018-02-07 15:01:53
Document Modified: 2018-02-07 15:01:53
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 3, 2016 will be considered. | |
| FR Citation | 81 FR 31650 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR